Header Logo

Connection

Co-Authors

Back to Details
This is a "connection" page, showing publications co-authored by CHAD CREIGHTON and ALEXANDER LAZAR.
CHAD CREIGHTON
Connection Strength
0.447
ALEXANDER LAZAR
  1. Correction: SAR405838: A Novel and Potent Inhibitor of the MDM2:p53 Axis for the Treatment of Dedifferentiated Liposarcoma. Clin Cancer Res. 2022 Jan 15; 28(2):431.
    View in: PubMed
    Score: 0.053
  2. Genomic, Pathway Network, and Immunologic Features Distinguishing Squamous Carcinomas. Cell Rep. 2018 04 03; 23(1):194-212.e6.
    View in: PubMed
    Score: 0.041
  3. SAR405838: A Novel and Potent Inhibitor of the MDM2:p53 Axis for the Treatment of Dedifferentiated Liposarcoma. Clin Cancer Res. 2016 Mar 01; 22(5):1150-60.
    View in: PubMed
    Score: 0.035
  4. Targeting the Notch pathway: A potential therapeutic approach for desmoid tumors. Cancer. 2015 Nov 15; 121(22):4088-96.
    View in: PubMed
    Score: 0.034
  5. NKD2, a negative regulator of Wnt signaling, suppresses tumor growth and metastasis in osteosarcoma. Oncogene. 2015 Sep 24; 34(39):5069-79.
    View in: PubMed
    Score: 0.033
  6. EZH2-miR-30d-KPNB1 pathway regulates malignant peripheral nerve sheath tumour cell survival and tumourigenesis. J Pathol. 2014 Feb; 232(3):308-18.
    View in: PubMed
    Score: 0.031
  7. CXCR4/CXCL12 mediate autocrine cell- cycle progression in NF1-associated malignant peripheral nerve sheath tumors. Cell. 2013 Feb 28; 152(5):1077-90.
    View in: PubMed
    Score: 0.029
  8. Localized and metastatic myxoid/round cell liposarcoma: clinical and molecular observations. Cancer. 2013 May 15; 119(10):1868-77.
    View in: PubMed
    Score: 0.029
  9. Uterine leiomyosarcoma management, outcome, and associated molecular biomarkers: a single institution's experience. Ann Surg Oncol. 2013 Jul; 20(7):2364-72.
    View in: PubMed
    Score: 0.029
  10. Dual targeting of mTOR and aurora-A kinase for the treatment of uterine Leiomyosarcoma. Clin Cancer Res. 2012 Sep 01; 18(17):4633-45.
    View in: PubMed
    Score: 0.028
  11. Survivin is a viable target for the treatment of malignant peripheral nerve sheath tumors. Clin Cancer Res. 2012 May 01; 18(9):2545-57.
    View in: PubMed
    Score: 0.027
  12. MiR-155 is a liposarcoma oncogene that targets casein kinase-1a and enhances ?-catenin signaling. Cancer Res. 2012 Apr 01; 72(7):1751-62.
    View in: PubMed
    Score: 0.027
  13. Increased midkine expression correlates with desmoid tumour recurrence: a potential biomarker and therapeutic target. J Pathol. 2011 Dec; 225(4):574-82.
    View in: PubMed
    Score: 0.026
  14. Diagnosis, management, and outcome of patients with dedifferentiated liposarcoma systemic metastasis. Ann Surg Oncol. 2011 Dec; 18(13):3762-70.
    View in: PubMed
    Score: 0.026
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.